Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 in ctDNA-Positive Stage II/III Colorectal Cancer
NCT07823322Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Oct 2026
- Primary completion
- May 2029
01
Overview
Phase 2, open-label, single-arm trial of INCA-33890 in colorectal cancer (CRC), sponsored by Incyte. Primary endpoint: Circulating tumor DNA clearance at 3 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
INCA-33890
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07823322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823322.